XYZAL ALLERGY 24HR (levocetirizine dihydrochloride) by Sanofi is levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of h 1 receptors. First approved in 2017.
Drug data last refreshed 23h ago · AI intelligence enriched 4d ago
XYZAL ALLERGY 24HR is an oral solution containing levocetirizine dihydrochloride, the active S-enantiomer of cetirizine. It is a selective H1-receptor antagonist indicated for allergic rhinitis and chronic urticaria. Levocetirizine demonstrates 2-fold higher H1-receptor affinity than racemic cetirizine, potentially offering enhanced efficacy.
Approaching loss of exclusivity in late 2027 signals transition planning and likely consolidation of commercial resources within the allergy franchise.
Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H 1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
Worked on XYZAL ALLERGY 24HR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
XYZAL ALLERGY 24HR offers limited career growth potential given its LOE-approaching status and zero current job openings. Professionals joining this product would focus on defensive market management and transition planning rather than expansion or innovation.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo